BioAge Labs (BIOA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is BIOA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

BioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 Transcript…

Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and BioAge Labs (NASDAQ: BIOA - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based o…

EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic d…

BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.56 per share a year ago.…

First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027…

BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

BioAge Labs (NASDAQ: BIOA - Get Free Report) and Royalty Pharma (NASDAQ: RPRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength …

Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep Origin's virtual scree…

Bank of America Corp DE acquired a new position in shares of BioAge Labs, Inc. (NASDAQ: BIOA) in a recent quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).…

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic dise…

BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline re…

BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and…

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic dise…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

